Market Research Logo

Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019

Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019

About Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia is a malignant condition characterized by increased production of lymphocytes. It has been observed that the cancer first affects B-lymphocytes and then it can spread to other parts of the body. This leukemia is diagnosed mostly at later stages because of the slow buildup of the cancerous cells. During the course of the disease, the malignancy spreads to the spleen, liver, and lymph nodes. The course of the disease is heterogeneous, and prognosis is difficult. Symptoms include swelling of the lymph nodes, fatigue, fever, infection, pain beneath the ribs, and weight loss. Chronic lymphocytic leukemia can be treated with radiation, steroids, chemotherapy, targeted therapy, transplants (bone marrow, stem cell), and surgical procedure to remove the spleen (splenectomy).

Technavio's analysts forecast the global chronic lymphocytic leukemia therapeutics market to grow at a CAGR of 18.52% over the period 2014-2019.

Covered in this Report

In this report, Technavio covers the present scenario and growth prospects of the global chronic lymphocytic leukemia therapeutics market for the period 2015-2019. To calculate the market size, we consider revenue generated from the sales of various drugs used in the treatment of chronic lymphocytic leukemia.

Based on the type of molecule, we group the market into two categories:

  • Biologics
  • Small molecules
Based on the route of administration, we group the market into two:
  • Oral
  • Parenteral
This report includes a discussion of the market in the following three regions:
  • Americas: The major countries focused in the Americas are the US, Canada, Mexico, and Brazil
  • EMEA: The major countries in this region are the UK, Germany, Italy, France, Spain and Middle
Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
  • APAC: The major countries in this region are Japan, China, Australia, Singapore, South Korea, and India. APAC is a major untapped market with many leading vendors in the global chronic lymphocytic leukemia therapeutics market.
  • The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. In addition, it discusses the major drivers and challenges, as well as the key trends.Key Regions
    • Americas
    • APAC
    • EMEA
    Key Vendors
    • F. Hoffmann-La Roche
    • Novartis
    • Teva Pharmaceutical Industries
    Other Prominent Vendors
    • Actavis
    • Amgen
    • Aryogen
    • Astellas
    • Bristol-Myers Squibb
    • Eagle Pharmaceuticals
    • Eisai
    • Fresenius Kabi
    • Genmab
    • Gilead Sciences
    • H. Lundbeck
    • Hospira
    • idd biotech
    • Immunomedics
    • Johnson & Johnson
    • Mundipharma
    • Mylan
    • Noxxon
    • Ono Pharmaceutical
    • PDL BioPharma
    • Pfizer
    • Pharmacyclics
    • Regeneron
    • Sagent Pharmaceutical
    • Sanofi
    • SymBio Pharmaceuticals
    • TheraMAB
    Key Market Driver
    • Increase in Patient Pool
    • For a full, detailed list, view our report
    Key Market Challenge
    • Unknown Disease Etiology
    • For a full, detailed list, view our report
    Key Market Trend
    • Strategic Alliances
    • For a full, detailed list, view our report
    Key Questions Answered in this Report
    • What will the market size be in 2019 and what will the growth rate be?
    • What are the key market trends?
    • What is driving this market?
    • What are the challenges to market growth?
    • Who are the key vendors in this market space?
    • What are the market opportunities and threats faced by the key vendors?
    • What are the strengths and weaknesses of the key vendors?


    Press Release

    Technavio Announces the Publication of its Research Report – Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019.

    Technavio recognizes the following companies as the key players in the Global Chronic Lymphocytic Leukemia Therapeutics Market: F. Hoffmann-La Roche, Novartis and Teva Pharmaceutical Industries.

    Other Prominent Vendors in the market are: Actavis, Amgen, Aryogen, Astellas, Bristol-Myers Squibb, Eagle Pharmaceuticals, Eisai, Fresenius Kabi, Genmab, Gilead Sciences, H. Lundbeck, Hospira, idd biotech, Immunomedics, Johnson & Johnson, Mundipharma, Mylan, Noxxon and Ono Pharmaceutical.

    Commenting on the report, an analyst from Technavio’s team said: “Vendors are increasingly forming strategic alliances to increase their market shares. Co-development agreements allow the sharing of regulatory and developmental experiences gained by either company to support pipeline candidates.”

    According to the report, “The increase in the patient pool for chronic lymphocytic leukemia is a major driver of the market. The elderly are more likely to be diagnosed with chronic lymphocytic leukemia. The older adult population is increasing globally, which indicates that the probability of getting chronic lymphocytic leukemia is also rising. As a result, the consumption of medications will increase, which will generate substantial revenue in the market.”

    Further, the report states that the unknown etiology of chronic lymphocytic leukemia is a major challenge because vendors are unable to target the basic cause of the disease. This makes it difficult for them to develop a drug that can effectively treat and cure the disease.

    Companies Mentioned

    F. Hoffmann-La Roche, Novartis and Teva Pharmaceutical Industries, Actavis, Amgen, Aryogen, Astellas, Bristol-Myers Squibb, Eagle Pharmaceuticals, Eisai, Fresenius Kabi, Genmab, Gilead Sciences, H. Lundbeck, Hospira, idd biotech, Immunomedics, Johnson & Johnson, Mundipharma, Mylan, Noxxon, Ono Pharmaceutical

    • Executive Summary
    • List of Abbreviations
    • Scope of the Report
      • Market Overview
      • Product Offerings
    • Product Profiles
      • Gazyva/Gazyvaro
        • MabThera/Rituxan
        • Arzerra
        • Treanda
    • Market Research Methodology
      • Market Research Process
      • Research Methodology
        • Table Market Research Methodology
    • Disease Overview
      • Understanding the Disease
        • Table Snapshot of Chronic Lymphocytic Leukemia
      • Types of Chronic Lymphocytic Leukemia
        • Table Types of Chronic Lymphocytic Leukemia
      • Symptoms
      • Diagnosis
        • Table Main Diagnostic Procedures to Determine Presence of Chronic Lymphocytic Leukemia
        • Table Other Diagnostic Procedures to Determine Presence of Chronic Lymphocytic Leukemia
      • Staging
        • Table Rai Stages of Chronic Lymphocytic Leukemia
        • Table Binet Stages of Chronic Lymphocytic Leukemia
      • Epidemiology
      • Management
        • Table Management of Chronic Lymphocytic Leukemia
      • Economic Burden
        • Table Economic Burden of Chronic Lymphocytic Leukemia
    • Introduction
    • Market Landscape
      • Market Overview
      • Market Size and Forecast
        • Table Global Chronic Lymphocytic Leukemia Therapeutics Market 2014-2019 ($ millions)
        • Table Global Chronic Lymphocytic Leukemia Therapeutics Market: Key Takeaways
      • Five Forces Analysis
    • Pipeline Portfolio
      • Key Information on Major Pipeline Molecules
        • RG 105 SC Formulation
        • Obinutuzumab/Venetoclax
        • RG 7596 (Polatuzumab Vedotin)
        • RG 7601 (Venetoclax)
          • Table Drug Candidates by Stage of Development
    • Market Segmentation by Route of Administration
      • Table Global Chronic Lymphocytic Leukemia Therapeutics Market by Route of Administration
      • Oral
      • Parenteral
    • Market Segmentation by Type of Molecule
      • Table Segmentation of Global Chronic Lymphocytic Leukemia Therapeutics Market by Type of Molecules
      • Small Molecules
      • Biologics
    • Geographical Segmentation
      • Table Global Chronic Lymphocytic Leukemia Therapeutics Market by Geography 2014
    • Buying Criteria
    • Market Growth Drivers
      • Table Drivers of Global Chronic Lymphocytic Leukemia Therapeutics Market
    • Drivers and their Impact
    • Market Challenges
      • Table Challenges in Global Chronic Lymphocytic Leukemia Therapeutics Market
    • Impact of Drivers and Challenges
    • Market Trends
      • Table Trends in Global Chronic Lymphocytic Leukemia Therapeutics Market
    • Trends and their Impact
    • Vendor Landscape
      • Competitive Scenario
        • Key News
        • M&A
      • Market Share Analysis 2014
        • F. Hoffmann-La Roche
          • Table Global Sales and YoY Growth Rate of Rituxan/MabThera 2010-2014 ($ millions)
        • Novartis
          • Table Global Sales and YoY Growth Rate of Arzerra 2010-2014 ($ millions)
          • Table Sales and YoY Growth Rate of Arzerra in US 2010-2014 ($ millions)
          • Table Sales and YoY Growth Rate of Arzerra in Europe 2010-2014 ($ millions)
          • Table Comparison of Revenue from Arzerra by Region 2010-2014 ($ millions)
        • Teva Pharmaceutical Industries
          • Table Global Sales and YoY Growth Rate of Treanda 2010-2014 ($ millions)
      • Other and Future Prominent Vendors
    • Key Vendor Analysis
      • F. Hoffmann-La Roche
        • Key Facts
        • Business Overview
        • Business Segmentation
          • Table Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
        • Business Segmentation by Revenue 2012 and 2013
          • Table F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
        • Sales by Geography
          • Table F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
          • Table F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
        • Business Strategy
        • Key Information
        • SWOT Analysis
      • Novartis
        • Key Facts
        • Business Description
        • Business Segmentation
          • Table Novartis AG: Business Segmentation
        • Revenue by Business Segmentation
          • Table Novartis AG: Revenue by Business Segmentation 2013
        • Revenue Comparison 2012 and 2013
          • Table Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
        • Sales by Geography
          • Table Novartis AG: Revenue by Geographical Segmentation 2013
        • Business Strategy
        • Key Developments
        • SWOT Analysis
      • Teva Pharmaceutical Industries
        • Key Facts
        • Business Overview
        • Business Segmentation
          • Table Teva Pharmaceutical Industries: Business Segmentation
        • Revenue by Business Segmentation
          • Table Teva Pharmaceutical Industries: Revenue by Business Segmentation 2013
        • Revenue Comparison 2012 and 2013
          • Table Teva Pharmaceutical Industries: Revenue by Business Segmentation 2012 and 2013 (US$ million)
        • Revenue Segmentation by Geography
          • Table Teva Pharmaceutical Industries: Revenue by Geographical Segmentation 2013
        • Business Strategy
        • Key Developments
        • SWOT Analysis
    • Other Reports in this Series

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report